BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET
Company Participants
Vimal Mehta - Chief Executive Officer
Richard Steinhart - Chief Financial Officer
Rob Risinger - Chief Medical Officer of Neuroscience
Matt Wiley - Chief Commercial Officer
Vince O'Neill - Chief R&D Officer of OnkosXcel Therapeutics
Conference Call Participants
Greg Harrison - Bank of America
Ram Selvaraju - H.C. Wainwright
Sumant Kulkarni - Canaccord Genuity
Colin Bristow - UBS
Robyn Karnauskas - Truist
Graig Suvannavejh - Mizuho
Corinne Jenkins - Goldman Sachs
Operator
Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will cover its alignment with the FDA on its TRANQUILITY program, provide an update on strategic financing, and review its financial results for the third quarter of 2023. At this time, all participants are in a listen-only mode. [Operator Instructions] After the presentation, there will be a question-and-answer session. [Operator Instructions]
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements.
Risk factors that may affect future results are detailed in the company's quarterly report on Form 10-Q for the quarter ended June 30, 2023, which can be found at www.bioxceltherapeutics.com or on www.sec.gov, and which will be updated in its quarterly report on Form 10-Q for the quarter ended September 30, 2023.
As a reminder, today's conference is being recorded.
Presenting on today's call are Dr. Vimal Mehta, Chief Executive Officer; and Richard Steinhart, Chief Financial Officer. Joining them for participation in the Q&A session are Matt Wiley, Chief Commercial Officer; Dr. Rob Risinger, Chief Medical Officer of Neuroscience; Dr. Vince O'Neill, Chief R&D Officer of OnkosXcel Therapeutics; and Dr. Frank Yocca, Chief Scientific Officer.
It is now my pleasure to turn the call over to Dr. Mehta.
Vimal Mehta
Thank you, operator. Good morning, and thank you for joining us.
Today, I begin with several exciting and highly anticipated updates on our recent development with our two late-stage clinical programs for BXCL501, TRANQUILITY and SERENITY III. In addition, I will cover important news about our financing terms with Oaktree Capital Management and Qatar Investment Authority. After this, I will touch briefly on updates for our IGALMI commercial activities and OnkosXcel Therapeutics. Rich will then cover the financial results for the third quarter.